MAP2K7 and acute lymphoblastic leukemia: Moreover, recurrent somatic mutations of the Ras/MEK/ERK pathway have been identified [42] and the MEK1/2 inhibitor Selumetinib showed strong cytotoxicity to leukemic iAMP21-positive cells, offering a possible targeted therapeutic strategy for iAMP21 B-ALL [42].